Additionally, TOMM20 is a prognostic biomarker in chordomas, which are a rare type of bone sarcomas, and TOMM20 expression is higher in recurrent and metastatic chordomas compared to primary tumors [34]. Here, TOMM20 is linked to bone sarcoma.